• Therapeutics Vaccine: Breast, Lung, Prostate Cancer
  • Molecular Targeted Therapy: Melanoma, Lung Cancer

There are an estimated 24.6 million people in the world living with cancer. According to the National Cancer Institute (NCI), in the U.S. alone, approximately 1.7 million people are newly diagnosed with cancer each year. The World Health Organization (WHO) has predicted that the global cancer incidence will increase by 50% between 2000 and 2020. According to the NCI, the economic impact of the cancer is estimated to be $126 billion in the U.S. alone, and is expected to reach $158 billion by 2020.

Despite the considerable success of the new therapies, there are significant unmet needs for cancer treatments. Traditional therapies, such as chemotherapy or radiotherapy, have serious side effects. New therapies, such as molecular targeted therapies or immunotherapies, have achieved tremendous success in clinic, but present certain limitations. One of the significant unmet needs of these therapies is the cost of treatment. Because monoclonal antibodies require sophisticated technology to be produced, the production costs are very high. Additionally, it has been shown that they have to be injected in large amounts to achieve clinical efficacy. As cancer becomes increasingly common globally, there is a significant need for new, innovative therapies.

We are developing i-αVLP technology to treat various types of cancers. Our goal is to develop next generation of targeted antibody agents as well as preventative and therapeutic vaccines that address these unmet needs by creating efficacious therapy that has less side effects and accessible.